Becton, Dickinson and Company (BDX) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Sell if holding. At $146.95, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 8.5%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3).
Becton Dickinson is a global medical technology company with three segments—BD Medical (IV systems, infusion pumps, pharmaceutical packaging), BD Life Sciences (diagnostics, biosciences), and BD Interventional (surgery, vascular, urology)—sold in over 100 countries to hospitals,... Read more
Sell if holding. At $146.95, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 8.5%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: Death cross but MACD improving, RSI 47. Score 5.3/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Becton, Dickinson and Company
Latest news
- Is It Time To Reconsider Becton Dickinson (BDX) After Its Recent Share Price Weakness? - Yahoo Finance — Yahoo Finance neutral
- Becton Dickinson Announces €600 Million Senior Notes Offering - The Globe and Mail — The Globe and Mail neutral
- Becton Dickinson Keeps Quarterly Dividend at $1.05 a Share, Payable on June 30 to Shareholders of Record on June 9 - mar — marketscreener.com neutral
- Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus — GuruFocus negative
- Becton Dickinson EVP Michael Feld sells $11,243 in stock By Investing.com - Investing.com Australia — Investing.com Australia neutral
Generated 2026-05-20T21:56:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-09Item 5.02MEDIUMRichard E. Byrd, EVP and President of the Interventional segment, departed effective April 6, 2026. No successor named in available filing text; no reason for departure cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $146.95, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 8.5%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3). Chart setup: Death cross but MACD improving, RSI 47. Prior stop was $137.57. Score 5.3/10, moderate confidence.
Take-profit target: $159.46 (+8.5% upside). Prior stop was $137.57. Stop-loss: $137.57.
Thin upside margin: 8.5%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Weak growth.
Becton, Dickinson and Company trades at a P/E of 25.6 (forward 10.9). TrendMatrix value score: 7.1/10. Verdict: Sell.
21 analysts cover BDX with a consensus score of 3.7/5. Average price target: $183.
What does Becton, Dickinson and Company do?Becton Dickinson is a global medical technology company with three segments—BD Medical (IV systems, infusion pumps,...
Becton Dickinson is a global medical technology company with three segments—BD Medical (IV systems, infusion pumps, pharmaceutical packaging), BD Life Sciences (diagnostics, biosciences), and BD Interventional (surgery, vascular, urology)—sold in over 100 countries to hospitals, clinics, and laboratories. A pending Reverse Morris Trust transaction will spin off the Biosciences and Diagnostic Solutions businesses combined with Waters Corporation, with BD receiving ~$4 billion pre-close. The company operates under an FDA consent decree affecting its Alaris infusion pump product line.